E. Ohman J or Asset Management AB Trims Stock Position in Lantheus Holdings, Inc. $LNTH

Key Points

• E. Ohman J or Asset Management AB has reduced its stake in Lantheus Holdings, Inc. by 21.1%, holding 18,732 shares worth approximately $1.53 million after selling 5,002 shares.
• In contrast, several institutional investors have increased their stakes in Lantheus, with ProShare Advisors LLC raising its position by 41.2% to a total of 22,646 shares, valued at $2.03 million.
• Lantheus reported a quarterly EPS of $1.57, missing estimates by $0.08, and its revenue of $378.05 million also fell short of expectations, marking a 4.1% decline year-over-year.

E. Ohman J or Asset Management AB trimmed its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 21.1% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 18,732 shares of the medical equipment provider's stock after selling 5,002 shares during the period. E. Ohman J or Asset Management AB's holdings in Lantheus were worth $1,533,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in LNTH. Cetera Investment Advisers raised its stake in shares of Lantheus by 22.7% in the 4th quarter. Cetera Investment Advisers now owns 23,358 shares of the medical equipment provider's stock valued at $2,090,000 after acquiring an additional 4,320 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Lantheus by 4.1% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 39,212 shares of the medical equipment provider's stock valued at $3,508,000 after acquiring an additional 1,531 shares during the period. ProShare Advisors LLC raised its stake in shares of Lantheus by 41.2% in the 4th quarter. ProShare Advisors LLC now owns 22,646 shares of the medical equipment provider's stock valued at $2,026,000 after acquiring an additional 6,606 shares during the period. State of Wyoming raised its stake in shares of Lantheus by 662.2% in the 4th quarter. State of Wyoming now owns 4,558 shares of the medical equipment provider's stock valued at $408,000 after acquiring an additional 3,960 shares during the period. Finally, Woodline Partners LP raised its stake in shares of Lantheus by 2.7% in the 4th quarter. Woodline Partners LP now owns 88,018 shares of the medical equipment provider's stock valued at $7,874,000 after acquiring an additional 2,340 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Trading Down 2.3%

LNTH opened at $51.74 on Tuesday. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49. The firm's 50 day moving average is $63.43 and its 200-day moving average is $80.91. The firm has a market capitalization of $3.52 billion, a P/E ratio of 13.76 and a beta of 0.15. Lantheus Holdings, Inc. has a 52-week low of $47.25 and a 52-week high of $118.21.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The medical equipment provider reported $1.57 EPS for the quarter, missing analysts' consensus estimates of $1.65 by ($0.08). The business had revenue of $378.05 million during the quarter, compared to analyst estimates of $389.69 million. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The business's revenue for the quarter was down 4.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.80 EPS. Analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. TD Cowen dropped their price objective on shares of Lantheus from $95.00 to $80.00 and set a "buy" rating for the company in a report on Monday. Mizuho decreased their price target on shares of Lantheus from $120.00 to $70.00 and set an "outperform" rating for the company in a research note on Thursday, August 7th. B. Riley cut their price objective on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research report on Monday, June 23rd. Truist Financial set a $63.00 price target on shares of Lantheus and gave the company a "hold" rating in a report on Monday, August 11th. Finally, William Blair restated a "market perform" rating on shares of Lantheus in a report on Wednesday, July 16th. Five analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, Lantheus presently has a consensus rating of "Moderate Buy" and a consensus price target of $89.67.

Insider Buying and Selling at Lantheus

In other news, insider Rajiv A. Patel sold 3,365,000 shares of the business's stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the transaction, the insider owned 3,477,227 shares of the company's stock, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the company's stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the sale, the insider directly owned 3,477,227 shares of the company's stock, valued at $195,246,296.05. The trade was a 49.18% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 6,812,000 shares of company stock valued at $382,427,380. Corporate insiders own 2.00% of the company's stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.